Medroxyprogesteronum [Inn-Latin]
Brand names,
Medroxyprogesteronum [Inn-Latin]
Analogs
Medroxyprogesteronum [Inn-Latin]
Brand Names Mixture
- Lunelle (Medroxyprogesterone + Estradiol)
Medroxyprogesteronum [Inn-Latin]
Chemical_Formula
C22H32O3
Medroxyprogesteronum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic/medrox.htm
Medroxyprogesteronum [Inn-Latin]
fda sheet
Medroxyprogesteronum [Inn-Latin]
msds (material safety sheet)
Medroxyprogesteronum [Inn-Latin]
Synthesis Reference
P. Ruggieri, C. Ferrari, U.S. Pat. 3,043,832 (1962)
Medroxyprogesteronum [Inn-Latin]
Molecular Weight
344.488 g/mol
Medroxyprogesteronum [Inn-Latin]
Melting Point
220 - 223.5 oC
Medroxyprogesteronum [Inn-Latin]
H2O Solubility
22.2mg/L
Medroxyprogesteronum [Inn-Latin]
State
Solid
Medroxyprogesteronum [Inn-Latin]
LogP
3.606
Medroxyprogesteronum [Inn-Latin]
Dosage Forms
Tablets; Depo injection
Medroxyprogesteronum [Inn-Latin]
Indication
Used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions.
Medroxyprogesteronum [Inn-Latin]
Pharmacology
Medroxyprogesterone is a synthetic progestin more potent than progesterone.
Medroxyprogesteronum [Inn-Latin]
Absorption
Rapidly absorbed from GI tract
Medroxyprogesteronum [Inn-Latin]
side effects and Toxicity
Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.
Medroxyprogesteronum [Inn-Latin]
Patient Information
Medroxyprogesteronum [Inn-Latin]
Organisms Affected
Humans and other mammals